Mukka Proteins (MUKKA) Fundamentals 2026 — P/E 13.3x, Revenue Analysis | SniperIQ
Mukka Proteins (MUKKA) is a India-listed Consumer Defensive company in Packaged Foods with a market capitalization of ₹690 Crore, trading at ₹23.00 on the NSE. This SniperIQ fundamentals page covers Mukka Proteins's valuation (P/E 13.3x, P/B 1.4x), profitability (net margin 3.6%), revenue (₹1,449 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mukka Proteins's market cap?
Mukka Proteins (MUKKA) has a market capitalization of approximately ₹690 Crore, trading at ₹23.00 on the NSE. Market cap moves with the live share price.
What is Mukka Proteins's P/E ratio?
Mukka Proteins's trailing twelve-month P/E ratio is 13.3x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Mukka Proteins?
Mukka Proteins runs a net profit margin of 3.6%, a gross margin of 15.8%, and an operating margin of 6.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mukka Proteins generate?
Mukka Proteins reported revenue of ₹1,449 Crore for fiscal year 2026, with net income of ₹52 Crore and earnings per share (EPS) of 1.74. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mukka Proteins pay a dividend?
Mukka Proteins does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Mukka Proteins financially healthy?
Mukka Proteins carries a debt-to-equity ratio of 1.56x and a current ratio of 1.23x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mukka Proteins a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mukka Proteins (MUKKA) the key facts are: market cap ₹690 Crore, P/E 13.3x, revenue ₹1,449 Crore, 52-week range 18.27-31.23. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Mukka Proteins's full fundamentals live
Get Mukka Proteins's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.